SITE MAP 
  HOME  
PHARMA
BIO TECHNOLOGY
MEDICAL TECHNOLOGY
  JOBS  
  FREE SUBSCRIPTION  
  Wednesday, October 8, 2008 SEARCH     
 
 
BIO AUSTRALIA
BIO CHINA
BIO INDIA
BIO INDONESIA
BIO JAPAN
BIO KOREA
BIO MALAYSIA
BIO NEW ZEALAND
BIO PHILIPPINES
BIO SINGAPORE
BIO TAIWAN
BIO THAILAND
 
 
Get the latest news on life sciences in your mail box
Name
E-Mail Id
 
 
Advertisement























 
Medical Technology  Policies  Story
FDA approves artificial cervical disc

Bangalore, July 18, 2007: The US Food and Drug Administration (FDA) approved for marketing the Prestige Cervical Disc, which is manufactured by Medtronic Sofamor Danek of Memphis. The Prestige Cervical Disc is the first artificial cervical disc for the treatment of cervical degenerative disc disease, one of the most common causes of neck and arm pain.
 
The device eases pain and restores function. The approval of this artificial disc will help people with cervical degenerative disc disease to gain access to another surgical option for treating this condition.
 
The cervical spine (neck region) consists of seven bones (called the vertebrae), which are separated from one another by intervertebral discs. These discs allow the neck to bend and rotate. The current surgical treatment involves removing a diseased or bulging disc in a patient’s neck and fusing two or more bony vertebrae. The Prestige Cervical Disc would instead replace the impaired natural disc.
 
The Prestige Cervical Disc consists of two main pieces of stainless steel that articulate against one another with a ball and trough (groove). After a doctor removes the impaired natural disc, the artificial disc is attached to the adjacent vertebrae with bone screws.
 
FDA based approval on the company's laboratory and animal testing, and on its clinical study of 541 patients. The clinical study showed that the device improved neck and/or arm pain, and was as safe and effective as cervical fusion, a common treatment for degenerative disc disease. The approval decision also took into account the recommendations of the Orthopedic and Rehabilitation Devices Panel of FDA’s Medical Devices Advisory Committee, which reviewed the product in September.
 
As a condition of approval, the company will conduct a post-approval study over the next seven years to evaluate the longer term safety and effectiveness of the device. FDA will continue to monitor the device as part of the agency’s overall effort to ensure that products remain safe and effective once they reach the marketplace.
 
FDA approved the PRESTIGE Cervical Disc as a class III device under the pre-market approval process. FDA’s regulation of medical devices is risk-based, with devices classified into low-risk (class I), moderate-risk (class II), or high-risk (class III) categories. The FDA regulatory program includes requirements for registration and listing of products, for high-quality production using good manufacturing practices and for post-market reporting of adverse events.

© BioSpectrum Bureau
  Email this articleComment on this article   Print this article
 
Advertisement





 
   
 
Google
BioSpectrumAsia.com BioSpectrumIndia.com Web

About BioSpectrum | How to Advertise | Jobs at BioSpectrum | Contact Us | Privacy Statement



CyberMedia Network Websites


[Voice&Data]  [PCQuest]  [CIOL]  [Dataquest]  [Living Digital]  [IDC India]
[DQ Channels]  [The DQweek]  [CyberMedia Careers]  
[CyberMedia Events] [CyberMedia Digital]  [Cyber Astro]  [CyberMedia India]  [Global Services]  [BioSpectrum]

 
Copyrights are reserved for BioSpectrum ; Designed by : Altered Black